Drug Trial Radar · NCT02704858
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Aug 1, 2017
Primary completion
Nov 30, 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Neonc Technologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will be up to 24 patients enrolled in Phase 1. There will be 25 patients enrolled in Phase 2a. For both phases of the study, NEO100 will be self-administered four times daily for a 28-day treatment cycles until disease progression, death or patient withdraw from study for any reason, whichever occurs first. Version 10 of the protocol changed the inclusion criteria for Phase 2a to limit inclusion to those patients with progressive or recurrent primary or secondary Grade IV gliomas expressing IDH1 mutations. Prior to the protocol amendment, 4 patients were enrolled who were IDH1 wild-type. Therefore, an additional 28 patients will be recruited for a total of 32 patients enrolled into Phase 2a of this study to have 35 evaluable cases. Version 12 of the protocol expanded the inclusion criteria for Phase 2a to include those patients with progressive or recurrent Grade III Astrocytoma expressing IDH1 mutations. Review of the literature specific to these patients found the same expected time to progression and death. As a result, the number of patients to enroll remains 32 to have 35 evaluable cases.
Conditions
- Glioblastoma Multiforme
Interventions
Perillyl alcoholDrug
Intranasal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: Up to 6 months
- Phase 2 Primary Outcome: Number of Participants Who Are Alive Each Month For 6 MonthsTime frame: Up to 6 months
- Phase 2 Primary Outcome: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related To TreatmentTime frame: 6 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
Sutter Health Research Institute
San Francisco, California
Saint John Cancer Institute
Santa Monica, California
Georgia Cancer Center (Augusta University)
Augusta, Georgia
Ochsner Health
New Orleans, Louisiana
Atlantic Health (Overlook Medical Center)
Summit, New Jersey
Northwell Health
New York, New York
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Cleveland Clinic
Cleveland, Ohio
Baylor Scott & White Health
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.